eamdacademy.org-zO7i-1792236768-m407002935 1792236768 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2025 4 2 Andreas Müller Stefan Weber Julia Hoffmann Lukas Schneider Tobias Klein 2025 10.68159/m407002935 https://eamdacademy.org/pub/journal/3/article/m407002935 Schuhmacher A, Hinder M, Stein AV, Hartl D, Gassmann O. Analysis of pharma R&D productivity–a new perspective needed. Drug Discov Today. 2023;28(10):103726. Granstrand O, Holgersson M. Innovation ecosystems: A conceptual review and a new definition. Technovation. 2020;90:102098. Kozarewicz P, Loftsson T. Novel excipients–Regulatory challenges and perspectives–The EU insight. Int J Pharm. 2018;546(1-2):176-9. Ting JM, Porter WW III, Mecca JM, Bates FS, Reineke TM. Advances in polymer design for enhancing oral drug solubility and delivery. Bioconjug Chem. 2018;29(4):939-52. Choi SH, Wang Y, Conti DS, Raney SG, Delvadia R, Leboeuf AA, et al. Generic drug device combination products: Regulatory and scientific considerations. Int J Pharm. 2018;544(2):443-54. Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev. 2021;175:113806. Chen Z, Liu X, Hogan W, Shenkman E, Bian J. Applications of artificial intelligence in drug development using real-world data. Drug Discov Today. 2021;26(5):1256-64. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77. Eichler HG, Koenig F, Arlett P, Enzmann H, Humphreys A, Pétavy F, et al. Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled, and transparent validation. Clin Pharmacol Ther. 2020;107(4):773-9. Walrave B, Talmar M, Podoynitsyna KS, Romme AG, Verbong GP. A multi-level perspective on innovation ecosystems for path-breaking innovation. Technol Forecast Soc Change. 2018;136:103-13. Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2018;23(3):652-60. Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867-8. Hines PA, Janssens R, Gonzalez-Quevedo R, Lambert AI, Humphreys AJ. A future for regulatory science in the European Union: the European Medicines Agency’s strategy. Nat Rev Drug Discov. 2020;19(5):293-4. Masterson F. Factors that facilitate regulatory approval for drug-device combination products in the European Union and United States of America: a mixed method study of industry views. Ther Innov Regul Sci. 2018;52(4):489-98. Kim JH, Kwon S, Seol JE, Kim MH, Kim SD. Regulatory framework for Drug-Device combination products in the united States, Europe, and Korea. Ther Innov Regul Sci. 2024;58(5):796-806. Phillips MA, Ritala P. A complex adaptive systems agenda for ecosystem research methodology. Technol Forecast Soc Change. 2019;148:119739. Van der Merwe J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics. 2020;12(5):393. Mochizuki M, Maeda H. Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan. Front Med Technol. 2024;6:1461460. Dong J, Gao H, Ouyang D. PharmSD: A novel AI-based computational platform for solid dispersion formulation design. Int J Pharm. 2021;604:120705. Chen L, Ding X, He Z, Huang Z, Kunnath KT, Zheng K, et al. Surface engineered excipients: I. improved functional properties of fine grade microcrystalline cellulose. Int J Pharm. 2018;536(1):127-37. Bhatia V, Dhingra A, Chopra B, Guarve K. Co-processed excipients: Recent advances and future perspective. J Drug Deliv Sci Technol. 2022;71:103316. Buckley LA, Sutherland JE, Borude P, Broudic K, Collin P, Hillegas A, et al. An Industry Perspective on the Use of Novel Excipients in Lipid Nanoparticles—Nonclinical Considerations. Int J Toxicol. 2025;44(3):196-210. Reis ME, Bettencourt A, Ribeiro HM. The regulatory challenges of innovative customized combination products. Front Med. 2022;9:821094. Tataru EA, Dooms M, Gonzaga-Jauregui C, Pasmooij AM, O’Connor DJ, Jonker AH. Drug–device combinations in rare diseases: Challenges and opportunities. Drug Discov Today. 2025;30(4):104343. Lou H, Lian B, Hageman MJ. Applications of machine learning in solid oral dosage form development. J Pharm Sci. 2021;110(9):3150-65. Jiang J, Ma X, Ouyang D, Williams RO III. Emerging artificial intelligence (AI) technologies used in the development of solid dosage forms. Pharmaceutics. 2022;14(11):2257. Franklin JM, Schneeweiss S. When and how can real world data analyses substitute for randomized controlled trials? Clin Pharmacol Ther. 2017;102(6):924-33. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-80. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. 2024. p. 1461-98. Aryal S, Blankenship JM, Bachman SL, Hwang S, Zhai Y, Richards JC, et al. Patient-centricity in digital measure development: co-evolution of best practice and regulatory guidance. NPJ Digit Med. 2024;7(1):128. Ciani O, Grigore B, Blommestein H, De Groot S, Möllenkamp M, Rabbe S, et al. Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies. Med Decis Making. 2021;41(4):439-52. Thompson DC, Bentzien J. Crowdsourcing and open innovation in drug discovery: recent contributions and future directions. Drug Discov Today. 2020;25(12):2284-93.